Silver Book Fact

A study of Parkinson’s disease treatments found that pramipexole is a cost-effective treatment for early and advanced Parkinson’s disease. The total cost-effectiveness ratio was $8,837/QALY for patients with early Parkinson’s disease and $12,294/QALY for patients with advanced disease.

Hoerger, Thomas J., Mohan V. Bala, Clayton Rowland, Marianne Greer, Elizabeth A. Chrischilles, and Robert G. Holloway. Cost Effectiveness of Pramipexole in Parkinsonâ??s Disease in the U.S. Pharmacoeconomics. 1998; 14(5): 541-57. http://www.ncbi.nlm.nih.gov/pubmed/10344917

Reference

Title
Cost Effectiveness of Pramipexole in Parkinsonâ??s Disease in the U.S.
Publication
Pharmacoeconomics
Publication Date
1998
Authors
Hoerger, Thomas J., Mohan V. Bala, Clayton Rowland, Marianne Greer, Elizabeth A. Chrischilles, and Robert G. Holloway
Volume & Issue
Volume 14, Issue 5
Pages
541-57
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Economic Value

Related Facts

  • Out-of-Pocket Costs, 5-Year Delayed Onset  
  • If an Alzheimer’s disease treatment breakthrough that delayed the age of onset by 5 years was introduced in 2015, by 2050 Medicare costs for people with the disease would be…  
  • Donepezil, a cholinesterase inhibitor, has been found to slow progression of Alzheimer’s disease in its early stages, delaying the need for nursing home care by an average of 30 months.  
  • Deep Brain Stimulation for Parkinson’s Adds QALYs and Saves Money
     
  • Research shows that use of donepezil leads to a 4-fold increase in drug costs; however, it significantly lowers overall medical costs, reducing medical treatment and prescription drug costs by $3,891…